although
recent
sar
coronaviru
sarscov
appear
contain
possibl
reemerg
sarscov
remain
due
threat
reemerg
overal
fatal
rate
rapid
dispers
viru
via
intern
travel
viabl
vaccin
candid
provid
protect
sar
clearli
need
develop
attenu
vsv
recombin
vsv
express
sar
coronaviru
sarscov
spike
protein
cell
infect
recombin
protein
synthes
glycosyl
approxim
asn
residu
transport
via
golgi
cell
surfac
mice
vaccin
vsv
develop
sarsneutr
antibodi
abl
control
challeng
sarscov
perform
month
month
singl
vaccin
also
demonstr
passiv
antibodi
transfer
antibodi
respons
induc
vaccin
suffici
control
sarscov
infect
vsvvector
sar
vaccin
could
signific
advantag
sar
vaccin
candid
describ
date
longterm
protect
sar
coronaviru
infect
confer
singl
immun
attenu
vsvbase
vaccin
fall
emerg
human
diseas
term
sar
sever
acut
respiratori
syndrom
drew
global
attent
diseas
character
atyp
pneumonia
accompani
high
fever
accord
world
health
organ
case
sar
health
care
worker
approxim
infect
individu
die
result
ill
death
rate
exceed
year
old
http
wwwwhointcsrsarsen
whoconsensuspdf
peiri
et
al
caus
agent
identifi
coronaviru
ksiazek
et
al
positivestrand
envelop
rna
viru
genom
sequenc
determin
rapidli
like
coronavirus
sar
coronaviru
sarscov
major
open
read
frame
two
encod
polymeras
four
encod
structur
protein
spike
membran
envelop
nucleocapsid
marra
et
al
rota
et
al
sar
protein
type
transmembran
glycoprotein
respons
viral
bind
host
cellular
receptor
identifi
angiotensin
convert
enzym
jeffer
et
al
follow
viral
fusion
host
cell
bosch
et
al
liu
et
al
yuan
et
al
immun
protein
coronavirus
mous
hepat
viru
mhv
transmiss
gastroenter
viru
tgev
infecti
bronchiti
viru
ibv
gener
protect
immun
virus
variou
anim
model
de
diego
et
al
ignjatov
galli
wessel
et
al
express
protein
sarscov
either
vitro
express
system
live
viral
vector
recent
report
gener
protect
sarscov
infect
anim
model
bisht
et
al
bukreyev
et
al
chen
et
al
gao
et
al
yang
et
al
spread
sar
curtail
public
health
measur
outbreak
success
contain
juli
although
sever
anim
suscept
sarscov
infect
sourc
outbreak
host
reservoir
uncertain
guan
et
al
possibl
reemerg
still
exist
event
sar
vaccin
would
valuabl
especi
protect
vulner
group
elderli
health
care
worker
studi
experiment
vesicular
stomat
viru
vsv
base
sar
vaccin
develop
test
vsv
neg
strand
rna
viru
nonseg
genom
encod
five
structur
protein
nucleocapsid
n
phosphoprotein
p
matrix
glycoprotein
g
rnadepend
rna
polymeras
l
vsv
elicit
strong
humor
cellular
immun
respons
varieti
anim
vsvbase
vaccin
shown
confer
immun
anim
model
respiratori
syncyti
viru
kahn
et
al
influenza
viru
robert
et
al
shivaid
measl
viru
schlereth
et
al
human
papilloma
viru
vsv
signific
advantag
mani
vaccin
vector
rel
small
rna
genom
accommod
insert
larg
foreign
gene
replic
exclus
cytoplasm
via
rna
intermedi
undergo
recombin
vsv
seroposit
also
extrem
low
gener
popul
rose
whitt
recombin
vsv
gener
plasmid
dna
system
employ
shown
less
pathogen
attenu
compar
natur
occur
strain
vsv
robert
et
al
caus
diseas
symptom
nonhuman
primat
given
intranas
oral
intramuscular
rout
present
studi
develop
recombin
attenu
vsv
express
sarscov
protein
test
sar
vaccin
mous
model
model
sarscov
replic
high
titer
respiratori
tract
allow
protect
sar
infect
assay
readili
vaccin
anim
follow
sarscov
challeng
determin
sarscov
protein
could
express
vsv
recombin
first
gener
cdna
clone
sar
gene
revers
transcript
pcr
amplif
rna
purifi
sarscovinfect
cell
next
construct
plasmid
sarscov
code
sequenc
insert
vsv
g
vsv
l
gene
fig
appropri
vsv
transcript
start
stop
site
flank
gene
recov
recombin
vsv
design
vsv
plasmid
use
publish
method
lawson
et
al
determin
recombin
viru
express
sar
protein
infect
bhk
cell
recov
viru
wt
vsv
metabol
label
cell
h
methionin
lysat
radiolabel
cell
analyz
sd
page
sinc
vsv
shut
host
protein
synthesi
wt
vsvinfect
cell
express
predominantli
five
viral
protein
l
g
n
p
vsvsinfect
cell
express
five
vsv
protein
fig
also
protein
expect
size
calcul
kda
assum
nglycosyl
potenti
site
verifi
ident
protein
immunoprecipit
cell
lysat
use
rabbit
polyclon
antibodi
cytoplasm
domain
immunoprecipit
protein
appear
two
band
fig
lane
potenti
repres
two
differ
glycosyl
state
examin
possibl
treat
protein
pngase
f
fig
lane
cleav
nlink
glycan
pngase
fdigest
yield
singl
band
approxim
kda
confirm
variabl
glycosyl
state
protein
respons
observ
size
heterogen
digest
immunoprecipit
protein
endo
h
endoglycosidas
cleav
unprocess
partial
process
glycan
protein
yield
two
band
fig
lane
endohresist
band
origin
size
account
total
protein
lower
band
repres
protein
yet
undergon
process
carbohydr
side
chain
account
total
protein
pulsechas
experi
puls
label
observ
express
vsv
endo
h
resist
within
min
chase
begun
data
shown
experi
conclud
protein
transport
exocyt
pathway
least
far
golgi
apparatu
endo
h
resist
acquir
determin
protein
transport
golgi
cell
surfac
examin
vsvsinfect
cell
use
indirect
immunofluoresc
microscopi
cell
infect
vsv
wt
vsv
fix
incub
serum
person
recov
sarscov
infect
secondari
alexa
fluor
antihuman
antibodi
use
visual
fluoresc
microscopi
found
sar
protein
clearli
express
cell
surfac
indic
strong
fluoresc
signal
visibl
vsvsbut
wt
vsvinfect
cell
fig
initi
immun
four
group
eight
mice
either
wt
vsv
vsv
sarscov
four
week
later
serum
collect
mous
determin
vsv
vsv
inocul
effect
perform
assay
measur
vsvneutral
antibodi
pool
sera
mice
infect
wt
vsv
vsv
vsvneutral
antibodi
titer
mice
infect
sarscov
detect
vsvneutral
antibodi
examin
individu
serum
sampl
neutral
antibodi
sarscov
tabl
infect
mice
vsv
gener
stronger
neutral
antibodi
respons
averag
sarsneutr
titer
sarscov
infect
sarscov
averag
sarsneutr
titer
sera
control
mice
immun
wt
vsv
detect
neutral
antibodi
titer
sarscov
mice
inocul
intranas
sarscov
show
clinic
symptom
infect
howev
viru
replic
high
titer
lung
nasal
turbin
nt
sarscov
replic
respiratori
tissu
peak
day
postinfect
viru
clear
within
week
examin
sarscov
replic
vaccin
control
anim
evalu
effect
vsv
vaccin
protect
sarscov
infect
three
group
four
mice
immun
either
wt
vsv
vsv
sarscov
four
week
later
mice
challeng
sarscov
day
challeng
lung
nasal
turbin
collect
correspond
viral
titer
determin
fig
control
mice
immun
wt
vsv
high
sar
viral
titer
lung
nasal
turbin
follow
sarscov
challeng
contrast
mice
immun
vsv
sarscov
complet
protect
control
sarscov
challeng
indic
sarscov
titer
detect
limit
lung
nasal
turbin
data
indic
vaccin
vsv
effect
primari
infect
sarscov
prevent
subsequ
sarscov
infect
determin
vsv
vaccin
could
provid
sustain
protect
sarscov
infect
similar
experi
carri
interv
immun
challeng
fig
two
day
challeng
sarscov
titer
lung
vsv
immun
mice
limit
detect
mice
fig
protect
sarscov
infect
immun
mice
balbc
mice
inocul
intranas
wt
vsv
vsv
sarscov
mice
challeng
week
later
tcid
sarscov
two
day
later
lung
nasal
turbin
collect
viral
titer
determin
addit
mice
challeng
month
immun
wt
vsv
vsvsar
sarscov
two
day
challeng
lung
nasal
turbin
collect
viral
titer
determin
b
limit
detect
log
tcid
g
tissu
lung
homogen
log
tcid
g
tissu
nasal
turbin
homogen
undetect
mice
titer
lung
sarscov
immun
mice
slightli
limit
detect
mice
undetect
mice
viral
titer
nasal
turbin
slightli
limit
detect
vsv
mice
sarscov
mice
immun
mice
mean
sar
viral
titer
nasal
turbin
vsvsand
sarscovinocul
mice
nearli
lower
viral
titer
nasal
turbin
wt
vsvimmun
mice
find
demonstr
vsv
vaccin
provid
sustain
protect
sarscov
challeng
may
provid
protect
immun
equal
better
primari
sarscov
infect
serum
mice
immun
vsv
confer
passiv
protect
vsv
infect
elicit
strong
humor
cellular
immun
respons
determin
antibodi
alon
could
provid
protect
sarscov
infect
serum
wt
vsv
vsv
sarscovinfect
mice
administ
intraperiton
mice
fig
mice
bled
h
administr
antisera
sarscovneutr
antibodi
titer
measur
mice
subsequ
challeng
sarscov
day
later
lung
collect
sarscov
titer
determin
sarscovneutr
antibodi
titer
detect
group
mice
receiv
vsv
antisera
sarscov
antisera
dilut
mice
abl
protect
sarscov
infect
upon
challeng
mice
receiv
wt
vsv
antisera
normal
mous
sera
measur
neutral
antibodi
sarscov
protect
sarscov
infect
upon
challeng
result
demonstr
vsv
elicit
strong
antibodi
respons
suffici
control
sarscov
infect
studi
use
attenu
vsv
vector
express
sarscov
protein
gene
sarscov
vsv
replic
cytoplasm
infect
cell
anticip
effici
express
sarscov
protein
recombin
vsv
without
problem
associ
nuclear
transcript
includ
mrna
modif
mrna
export
nucleu
level
protein
express
obtain
vsv
recombin
clearli
suffici
gener
longterm
protect
immun
sarscov
anim
model
level
sarscovneutr
antibodi
titer
follow
vsv
immun
equal
better
elicit
follow
primari
infect
sarscov
although
passiv
transfer
immun
sera
demonstr
antibodi
induc
either
vsv
sarscov
inocul
suffici
prevent
sarscov
infect
cellular
immun
respons
may
also
contribut
protect
similarli
shown
coronavirus
mous
hepat
viru
type
antibodymedi
immun
suffici
protect
pope
et
al
furthermor
complet
protect
sar
viral
replic
lower
respiratori
tissu
vsvsimmun
mice
observ
challeng
administ
month
postimmun
suggest
prolong
protect
may
provid
singl
immun
vsv
first
studi
show
longterm
protect
immun
experiment
sarscov
vaccin
previou
studi
vaccin
mice
vsv
express
influenza
hemagglutinin
found
protect
influenzaneutr
antibodi
titer
longliv
declin
cours
one
year
robert
rose
unpublish
data
vsvbase
sar
vaccin
could
signific
advantag
previous
describ
sar
vaccin
bisht
fig
inhibit
sarscov
replic
transfer
serum
immun
mice
sera
uninfect
mice
mice
immun
vsv
sarscov
dilut
pb
wt
vsv
inject
mice
serum
collect
mice
measur
sarscovneutr
antibodi
titer
limit
detect
reciproc
dilut
mice
infect
sarscov
day
later
lung
harvest
measur
sarscov
titer
limit
detect
log
tcid
g
bukreyev
et
al
chen
et
al
gao
et
al
yang
et
al
preexist
immun
vsv
rare
human
popul
effect
vaccin
candid
base
adenoviru
parainfluenza
viru
could
limit
high
preval
preexist
immun
vector
human
popul
vaccin
base
modifi
vaccinia
ankara
mva
could
face
problem
parent
vaccinia
viru
use
worldwid
smallpox
vaccin
extens
immun
vaccinia
especi
older
popul
suscept
sar
crotti
et
al
dna
vaccin
effect
especi
small
anim
model
howev
efficaci
human
yet
demonstr
vsv
addit
advantag
grow
high
titer
cell
line
vero
approv
human
vaccin
product
vsv
also
effect
low
dose
robert
et
al
robert
et
al
effect
intranas
vaccin
egan
et
al
inactiv
sarscov
also
shown
elicit
immun
respons
qu
et
al
takasuka
et
al
tang
et
al
xiong
et
al
zhang
et
al
howev
product
vaccin
would
carri
inher
risk
exposur
sarscov
handl
larg
volum
infecti
materi
could
result
accident
infect
secondari
spread
addit
might
concern
proper
complet
inactiv
viru
sarscov
protein
express
vsv
estim
gel
mobil
approxim
kda
convert
kda
upon
remov
nlink
glycan
base
calcul
estim
least
potenti
nlink
glycosyl
site
use
assum
kda
per
nlink
glycan
also
demonstr
express
vsv
recombin
move
golgi
apparatu
acquir
endo
h
resist
express
label
period
contain
endohresist
glycan
pulsechas
experi
puls
label
observ
express
vsv
endo
h
resist
within
min
chase
begun
data
shown
final
readili
observ
protein
cell
surfac
result
indic
protein
move
effici
exocyt
pathway
express
absenc
sar
viru
protein
exposur
protein
cell
surfac
infect
cell
like
import
induct
neutral
antibodi
respons
coronaviru
vaccin
includ
mhv
ibv
tgev
effect
control
infect
contrast
vaccin
felin
infecti
periton
viru
use
protein
viru
antigen
enhanc
diseas
cat
vennema
et
al
enhanc
infect
observ
present
mous
model
previou
studi
howev
sinc
sarscov
caus
diseas
mice
model
may
reveal
effect
mild
moder
hepat
lesion
observ
singl
set
experi
ferret
vaccin
mva
mvasar
mvasarsn
challeng
sarscov
czub
et
al
weingartl
et
al
signific
lesion
unclear
sinc
occur
mva
vaccin
sarscovchalleng
anim
well
unvaccin
pb
control
sarscov
challeng
anim
although
two
three
ferret
receiv
mvasar
vaccin
slightli
larger
lesion
follow
sarscov
challeng
difficult
ascertain
whether
hepat
diseas
enhanc
variabl
furthermor
sarscov
diseas
primarili
respiratori
diseas
lesion
liver
may
littl
relev
sarscov
diseas
observ
may
therefor
isol
use
vector
anim
model
specif
combin
potenti
sarscovenhanc
diseas
previous
vaccin
sarsexpos
anim
requir
studi
model
close
mimic
human
diseas
sarscov
gene
amplifi
rna
virusinfect
cell
provid
dr
william
bellini
cdc
revers
transcriptionpcr
use
superscript
onestep
rtpcr
long
templat
invitrogen
carlsbad
ca
follow
primer
use
rtpcr
pcr
product
digest
xhoi
nhei
ligat
schnell
et
al
also
digest
enzym
result
clone
pvsvsar
sequenc
gene
sequenc
match
publish
sequenc
genbank
access
except
silent
mutat
nucleotid
g
instead
recombin
viru
recov
previous
describ
lawson
et
al
briefli
cell
infect
fuerst
et
al
h
transfect
pvsvsar
support
plasmid
pbsn
pbsm
pbsg
pbsl
h
two
day
transfect
media
transfer
onto
fresh
cell
media
collect
day
stock
vsv
singl
plaqu
grown
recombin
wildtyp
wt
vsv
lawson
et
al
also
grown
order
detect
sarscov
protein
antibodi
direct
ctermin
domain
produc
rabbit
immun
boost
peptid
kfdeddsepvlkgvklhyt
coupl
klh
serum
collect
affin
purifi
pocono
rabbit
farm
laboratori
inc
canadensi
pa
cell
infect
either
vsvsar
wt
vsv
multipl
infect
moi
h
cell
wash
twice
methioninefre
dulbecco
modifi
eagl
medium
dmem
incub
dmem
contain
aci
methionin
h
cell
wash
phosphatebuff
salin
pb
lyse
deterg
solut
nonidet
deoxychol
mm
tri
hcl
ph
mm
edta
protein
sampl
analyz
sd
page
sar
immunoprecipit
lysat
stail
antiserum
dilut
c
overnight
protein
asepharos
zyme
laboratori
inc
san
francisco
ca
ad
allow
incub
h
room
temperatur
sepharos
wash
hntg
buffer
mm
hepe
mm
nacl
mm
edta
mm
egta
glycerol
triton
immunoprecipit
treat
endoglycosidas
endo
h
peptid
nglycosidas
pngase
f
new
england
biolab
beverli
accord
manufactur
instruct
cell
seed
onto
glass
coverslip
infect
either
vsv
wt
vsv
moi
h
infect
cell
wash
pb
fix
paraformaldehyd
cell
wash
pbsglycin
mm
coverslip
incub
dilut
serum
person
recov
sar
provid
dr
william
bellini
cdc
coverslip
wash
pb
glycin
incub
dilut
alexa
fluor
goat
anti
human
igg
molecular
probe
eugen
coverslip
wash
mount
slide
use
glycerol
contain
npropylgal
cell
observ
nikon
microphotfx
epifluoresc
microscop
use
object
three
group
eight
bablc
mice
inocul
intranas
either
pfu
wt
vsv
pfu
vsvsar
tcid
sarscov
twentyeight
day
immun
serum
collect
mice
measur
neutral
antibodi
titer
four
mice
group
challeng
tcid
sarscov
previous
describ
two
day
later
lung
nasal
turbin
mice
collect
determin
viral
titer
remain
four
mice
challeng
month
postimmun
lung
nasal
turbin
collect
day
challeng
viral
titer
determin
vsvneutral
antibodi
titer
measur
determin
highest
dilut
serum
could
prevent
kill
monolay
cell
vsv
sarscovneutr
antibodi
titer
determin
evalu
serum
dilut
cytopath
effect
cpe
sarscov
inhibit
half
well
contain
vero
monolay
sera
mice
immun
wt
vsv
vsv
sarscov
collect
heat
inactiv
two
group
six
mice
inject
intraperiton
ip
al
wt
vsv
vsv
immun
sera
two
addit
group
six
mice
also
inject
ip
al
sar
immun
sera
dilut
pb
sera
mice
serum
collect
mous
determin
neutral
antibodi
titer
sarscov
mice
inocul
tcid
sarscov
two
day
later
lung
collect
mous
viral
titer
determin
describ
